140 related articles for article (PubMed ID: 23718922)
1. Determination of APTT factor sensitivity--the misguiding guideline.
Lawrie AS; Kitchen S; Efthymiou M; Mackie IJ; Machin SJ
Int J Lab Hematol; 2013 Dec; 35(6):652-7. PubMed ID: 23718922
[TBL] [Abstract][Full Text] [Related]
2. Do PT and APTT sensitivities to factors' deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?
Martinuzzo M; Barrera L; Rodriguez M; D'Adamo MA; López MS; Otaso JC
Int J Lab Hematol; 2015 Dec; 37(6):853-60. PubMed ID: 26338156
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
Lawrie AS; Kitchen S; Purdy G; Mackie IJ; Preston FE; Machin SJ
Clin Lab Haematol; 1998 Jun; 20(3):179-86. PubMed ID: 9681235
[TBL] [Abstract][Full Text] [Related]
5. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
Favaloro EJ; Kershaw G; Mohammed S; Lippi G
Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
[TBL] [Abstract][Full Text] [Related]
6. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
[TBL] [Abstract][Full Text] [Related]
7. APTT critical value establishment in four different reagent/instrument systems based on single factor deficiencies.
Huang H; Qu T; Hu M; Chen Z; Fan K; Mo X
Ann Hematol; 2024 Jun; ():. PubMed ID: 38935318
[TBL] [Abstract][Full Text] [Related]
8. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
9. Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Suzuki N; Tamura S; Kikuchi R; Katsumi A; Kojima T; Matsushita T
Int J Lab Hematol; 2024 Aug; 46(4):705-713. PubMed ID: 38426662
[TBL] [Abstract][Full Text] [Related]
10. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time.
Burns ER; Goldberg SN; Wenz B
Am J Clin Pathol; 1993 Aug; 100(2):94-8. PubMed ID: 8356955
[TBL] [Abstract][Full Text] [Related]
11. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Welsch DJ; Novotny WF; Wun TC
Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Sysmex CS5100 coagulation analyzer and comparison to the Stago STA-R analyzer for routine coagulation parameters.
Geens T; Vertessen F; Malfait R; Deiteren K; Maes MB
Int J Lab Hematol; 2015 Jun; 37(3):372-81. PubMed ID: 25233923
[TBL] [Abstract][Full Text] [Related]
13. Activated partial thromboplastin time derivative curves: helpful diagnostic tool in mixing test interpretation.
Esmedere Eren S; Karakukcu C; Ciraci MZ; Ustundag Y; Karakukcu M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):410-414. PubMed ID: 29708898
[TBL] [Abstract][Full Text] [Related]
14. A study of atypical APTT derivative curves on the ACL TOP coagulation analyser.
Solano C; Zerafa P; Bird R
Int J Lab Hematol; 2011 Feb; 33(1):67-78. PubMed ID: 20649909
[TBL] [Abstract][Full Text] [Related]
15. Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom.
Lincz LF; Scorgie FE; Johnston CI; O'Leary M; Prasad R; Seldon M; Favaloro E; Isbister GK
Pathology; 2014 Aug; 46(5):444-9. PubMed ID: 24977733
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
Shetty S; Ghosh K; Mohanty D
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):493-7. PubMed ID: 12851537
[TBL] [Abstract][Full Text] [Related]
17. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of high-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value.
Kanahara M; Kai H; Okamura T; Wada T; Suda K; Imaizumi T; Sagawa K
Thromb Res; 2008; 121(6):781-5. PubMed ID: 17904620
[TBL] [Abstract][Full Text] [Related]
19. A comparison of two APTT reagents which use silica activators.
Ray MJ; Hawson GA
Clin Lab Haematol; 1989; 11(3):221-32. PubMed ID: 2556232
[TBL] [Abstract][Full Text] [Related]
20. Consequences for the APTT due to direct action of factor XIa on factor X, resulting in bypassing factors VIII-IX.
Kluft C; van Leuven CJ
Thromb Res; 2015 Jan; 135(1):198-204. PubMed ID: 25467084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
